Friday, 22 Jun 2018

You are here

Biosimilar Data at #EULAR2018

Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.

Abstract THU0222 reported data on 143 patients from a single clinic, ~50% had RA, and multi-switching between the etanercept originator and the biosimilar had no effect on retention of etanercept. In fact there may have even been a small protective effect of multi-switching on etanercept retention. Now it’s a single centre and its observational data so must be treated with a degree of caution but it’s an interesting result.

Another study from a large UK centre looked at the rate of flare after changing from the originator to the biosimilar and for etanercept found 4 out of 63 with RA flares after the change and 2 of 19 with SpA and 2 of 19 with PsA. For the infliximab biosimilar the flare rates was 2-4% across indications. Their conclusions were that the rate of flares was low and this supported single switch (THU0204)

Data from the TURKBIO registry on 614 patients showed that Remsima the infliximab biosimilar had better retention rates than Remicade over 5 years (THU 0218). There is also RABBIT registry data using Kaplan-Meier estimates showed that patients who were bionaive and were commenced on both the originator and biosimilar etanercept. The SB4 biosimilar (n = 250) was stopped around half the rate (14%) and the etanercept originator (n = 317) (THU0192).

So there seems to be an enlarging amount of data that is reassuring around switching patients to biosimilars and drug survival on biosimilars. But it is important to remember that registry and observational data has limitations so care has to be taken to put excessive weight on these types of results.

Add new comment

More Like This

EULAR 2018 - Day 4 Report

The EULAR 2018 wound down on Saturday with fewer oral presentations but many posters.  In my last report I put together a collection of impressions and some thematic highlights not covered in previous reports. Also some of these represent research and reporting trends – some healthy, others not so – that were evident at the EULAR 2018 meeting.

Pain 

High Biologic Blood Levels Increases the Risk of Infections in RA

A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs.  While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.

In abstract OP0229 UK researchers have shown high biologic blood levels are associates with an increased risk of total infections in RA, but not serious infetions.

Abbvie Highlights Upadacitinib Trials at EULAR18

Abbvie press releases feature the results from 3 new trials to be presented during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe rheumatoid arthritis.

Vedolizumab Implicated in Exacerbations of SpA in IBD Patients

Beloved by gastroenterologist for treatment of inflammatory bowel disease (IBD), α4β7 integrin receptor vedolizumab (VDZ) has probably caught attention of many rheumatologist since the time it entered the market; largely for what it won't do for inflammatory arthritis.

JAK Inhibition in Autoinflammatory Syndromes Interferonopathies

While many autoinflammatory syndromes are driven and managed with select inhibition of IL-1, IL-18 or IL-6, a subset are driven by type I interferon and are referred to as interferonopathies. These monogenic IFN–mediated disorders present in infancy with fevers, systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality.